INS and type 2 diabetes mellitus: We carried out a trial to examine the safety and efficacy of switching from MDI to IDegLira in relatively well controlled (HbA1c ≤ 7.5% [58 mmol/mol]) but potentially overtreated subjects with type 2 diabetes using low total daily insulin dose (TDD).